Clinical Trials Logo

Clinical Trial Summary

This is a randomized, double blind, placebo parallel-controlled phase III clinical trial to evaluate the efficacy, immunogenicity and safety of the inactivated SARS-CoV-2 Vaccine (Vero cell) in Argentine healthy population aged between 18 and 85 years old.


Clinical Trial Description

SARS-CoV-2 belongs to β Coronavirus family and is a pathogen that can spread across races and is easy to cause respiratory diseases. In December 2019, patients with pneumonia of unknown causes showed fever, cough, dyspnea, accompanied by medical imaging change of patchy diffuse infiltration of the lungs [2]. Through genome sequencing and analysis of lower respiratory tract alveolar lavage fluid samples from patients with pneumonia of unknown cause, a novel coronavirus different from any known virus was found. The World Health Organization WHO named the virus 2019 novel coronavirus, or 2019-nCoV for short, and the disease caused by the virus was named COVID-19. WHO listed the epidemic as a public health emergency of international concern. With the spread of the SARS-CoV-2 epidemic in the world, vaccines have become the best weapon for epidemic prevention and control. At present, no vaccine to prevent coronavirus disease (COVID-19) in 2019 has been approved for listing. Based on the experience accumulated in the research and development of coronavirus vaccines in the past, the target of vaccines is also mainly focused on S protein. Inactivated Virus Vaccine inactivates the virus obtained by culture by heating or chemical methods. The inactivated virus loses its pathogenicity and retains the main antigenic characteristics of the virus capsid, which can stimulate the specific immune response of human body. The inactivated SARS-CoV-2 vaccine (Vero cell) is prepared by inoculating African green monkey kidney cells (Vero cell) with the SARS-CoV-2 HB02 strain, culturing, harvesting, inactivating, clarifying, concentrating, purifying, and adding aluminum hydroxide adjuvant. After inoculating the vaccine, the recipients can produce immune response to prevent diseases caused by SARS-CoV-2. The inactivated SARS-CoV-2 vaccine (Vero cell) is prepared by inoculating African green monkey kidney cells (Vero cell) with the SARS-CoV-2 HB02 strain, culturing, harvesting, inactivating, clarifying, concentrating, purifying, and adding aluminum hydroxide adjuvant. After inoculating the vaccine, the recipients can produce immune response to prevent diseases caused by SARS-CoV-2. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04560881
Study type Interventional
Source Laboratorio Elea Phoenix S.A.
Contact
Status Completed
Phase Phase 3
Start date September 16, 2020
Completion date December 13, 2021

See also
  Status Clinical Trial Phase
Terminated NCT04449380 - Clinical Study for the Treatment With Interferon-ß-1a (IFNß-1a) of COVID-19 Patients Phase 2
Active, not recruiting NCT05208983 - SafeTy and Efficacy of Preventative CoVID Vaccines
Completed NCT05364268 - Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
Completed NCT05268679 - Covid-19 Vaccine Response in Heart Transplant Recipients
Completed NCT05446961 - Clinical Study to Evaluate the Effect of Food Supplement in People Infected With Coronavirus Phase 2
Terminated NCT04847583 - A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients Phase 2
Terminated NCT04778059 - Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19 Phase 2
Terminated NCT04786808 - Risk Factors for COVID-19 Mortality
Completed NCT05514691 - Evaluation of Clinical Performance and Usability of iStatis COVID-19 Ag Rapid Test at POC N/A
Withdrawn NCT05085574 - Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1) Phase 2
Completed NCT05489367 - Does COVİD-19 m-RNA Vaccine Affect Fertility and Over Reserve ?
Withdrawn NCT05133635 - High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19 Phase 4
Active, not recruiting NCT05077332 - LEAP-CT for Treatment of COVID-19 Patients (Master Protocol) Phase 2
Terminated NCT05077969 - Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients (Addendum 2) Phase 2
Completed NCT05371561 - Effect of PPE on Children's Fear in Dental Office N/A